Antiseizure medication in patients with meningioma: a retrospective cohort study on the long-term impact on depression, anxiety and neurocognitive functioning - Takeaways - MDSpire

Antiseizure medication in patients with meningioma: a retrospective cohort study on the long-term impact on depression, anxiety and neurocognitive functioning

  • By

  • L. Laribi

  • J. C. C. Scheepens

  • A. H. Zamanipoor Najafabadi

  • M. J. Vos

  • W. R. van Furth

  • S. M. Peerdeman

  • M. J. B. Taphoorn

  • P. B. Van der Meer

  • J. A. F. Koekkoek

  • June 6, 2025

  • 0 min

Share

  • 1

    Meningiomas are the most common primary intracranial tumors in adults, with over one third of patients experiencing seizures during their disease.

  • 2

    Antiseizure medications (ASMs) are recommended after a single seizure in patients with intracranial tumors, including meningiomas.

  • 3

    Levetiracetam is the most commonly used ASM in meningioma patients, as it has fewer drug interactions compared to enzyme-inducing ASMs.

  • 4

    Limited research exists on the impact of ASM use on mood and cognition specifically in meningioma patients, necessitating further investigation.

  • 5

    This study aims to evaluate the association of ASM use, particularly levetiracetam, with depression, anxiety, and neurocognitive functioning in meningioma patients.

Original Source(s)

Antiseizure medication in patients with meningioma: a retrospective cohort study on the long-term impact on depression, anxiety and neurocognitive functioning

  • by L. Laribi, J. C. C. Scheepens, A. H. Zamanipoor Najafabadi, M. J. Vos, W. R. van Furth, S. M. Peerdeman, M. J. B. Taphoorn, P. B. Van der Meer, J. A. F. Koekkoek

  • June 6, 2025

Related Content

Are clinical, psychophysical, or psychological variables helpful for discriminating patients with tension type headache? A diagnostic accuracy study

Mind Matters: Mental Health and Diabetes Management

Risk prediction models for depression in older adults with cancer